I'm LongbridgeAI. Here is the key information I extracted- The company announced a 2.6 billion dollar licensing agreement with Starna Therapeutics focusing on CAR-T therapies for autoimmune diseases and remained a subject of industry-wide discussions regarding artificial intelligence integration.…
The Week
Pfizer (PFE.US) fell 5.16% this week to close at $27.40. The S&P 500 dropped 8.61% over the same period, so Pfizer outperformed by roughly 3.45 percentage points. The daily bars show a one-way slide: the stock opened Monday (16 November) at $29.23 and drifted lower through the week, hitting a low of $27.35 on Friday (20 November) before settling at $27.40. Weekly amplitude came in at 6.6%, and average daily volume of about 37.4 million shares ran roughly 20% above the 60-day median, reflecting heavier turnover.
Key Events
Two threads ran through Pfizer’s week: a sizeable licensing move in autoimmune disease, and the sector-wide conversation around AI in drug development. On Monday, a media report questioned whether Pfizer was undervalued in its $1.5 billion Berobenatide funding deal. On Wednesday, Pfizer announced a licensing agreement with Starna Therapeutics for autoimmune disease treatments; on Thursday, details emerged pointing to a $2.6 billion deal centred on CAR-T therapies. The same day, an industry note highlighted how pharmaceutical majors are stepping up AI investment to cut costs and shorten timelines. On Tuesday, Leerink Partners kept its hold rating on Pfizer, the only rating action of the week.
Analyst Ratings
Across 28 institutions covering Pfizer, 8 rate it buy, 1 rate it overweight, 17 rate it hold, 1 rates it underweight and 1 rates it sell. The consensus recommendation is hold, with a consensus target price of $30.22, about 10.3% above the latest close of $27.40. The target range is wide, from $25 to $37, pointing to meaningful disagreement among analysts. Within the pharmaceutical industry, Pfizer ranks 2nd out of 207 companies by rating strength.
The Week Ahead
Tuesday (24 November) brings a dense run of US macro data: FHFA house prices, the Case Shiller 20-city index, consumer confidence and the Richmond Fed composite index, all of which could shift sentiment and rate expectations. On the corporate side, Pfizer reports fiscal 2026 full-year results before the open on 2 February 2027, with consensus estimates around EPS of $1.54 and revenue of roughly $63.1 billion. The follow-through on this week’s $2.6 billion CAR-T licensing deal with Starna is also worth tracking.
In Short
Pfizer held up better than the broader market during a sector-wide pullback, while the analyst setup remains cautiously constructive: the consensus target sits above spot, and most brokers rate the stock buy or overweight. Yet the latest trading day shows large and medium orders on the net selling side, with small orders the net buyers. The tension is between a moderately supportive rating distribution and money that has not yet turned convincingly in one direction. What comes next depends on execution of the CAR-T licensing deal and how the dense macro calendar next week feeds into pharma risk appetite.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.
